Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM-CSF + cytarabine + etoposide + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination chemotherapy regimen consisting of GM-CSF (granulocyte colony-stimulating factor), cytarabine, etoposide, and mitoxantrone. This regimen is primarily used for the treatment of relapsed or refractory acute myeloid leukemia (AML) and other high-grade myeloid neoplasms. GM-CSF stimulates bone marrow to produce white blood cells, while the three chemotherapeutic agents target rapidly dividing cancer cells through different mechanisms.
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)DNA polymerase familyTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on GM-CSF + cytarabine + etoposide + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM-CSF + cytarabine + etoposide + mitoxantrone.